Obesity Firm Kailera Therapeutics Up 63% After $625 Million IPO

Kailera Therapeutics, an obesity-focused biotech firm, saw its stock rise 63% on the New York Stock Exchange after a $625 million initial public offering (IPO). The surge highlights investor confidence in the company's potential in the weight-loss drug market.